Both DTX3L and ARTD9 have been shown to be involved in drug resistance in HR- DLBCL associated with a R-CHOP chemotherapy-induced microenvironment gene expression signature [469, 470, 472], see next sections. The gene discussed is DTX3L; the disease is diffuse large B-cell lymphoma.